Review of the Early Access to Medicines Scheme (EAMS)

Tender description

The Early Access to Medicines Scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation, when there is a clear unmet medical need. The scheme demonstrates a commitment from the UK to pharmaceutical innovation, providing a platform for drugs to be brought to patients at a much faster rate than ever before. We are looking for organisations that will work closely with the team to inform their wider work in developing possible solutions to the challenges of workstream 2 i.e. how the current UK landscape for development and regulation of new healthcare technologies could be streamlined and future-proofed. This review of EAMS will look at whether and how EAMS has accelerated development of new products, gathering evidence and providing analytical support to workstream 2. This work will be delivered in parallel with a significant piece of work looking at how the current UK landscape for development and regulation of new healthcare technologies could be streamlined and future-proofed (for which see ITT ref number 59941).